ID   MWCL-1
AC   CVCL_M086
SY   MWCL.1; MWCL1
DR   CLO; CLO_0037225
DR   cancercelllines; CVCL_M086
DR   Cosmic; 1762457
DR   Cosmic; 2645644
DR   LINCS_HMS; 51098
DR   LINCS_LDP; LCL-2109
DR   Wikidata; Q28914904
RX   PubMed=21415268;
RX   PubMed=22950966;
RX   PubMed=23321251;
RX   PubMed=24189269;
RX   PubMed=25382610;
RX   PubMed=25853860;
CC   Sequence variation: Mutation; HGNC; HGNC:7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (PubMed=23321251).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val143Ala (c.428T>C); ClinVar=VCV000804214; Zygosity=Hemizygous (PubMed=21415268).
CC   Omics: Array-based CGH.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C80307; Waldenstrom macroglobulinemia
DI   ORDO; Orphanet_33226; Waldenstrom macroglobulinemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   73Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 19-12-24; Version: 16
//
RX   PubMed=21415268; DOI=10.1182/blood-2010-12-326868;
RA   Hodge L.S., Novak A.J., Grote D.M., Braggio E., Ketterling R.P.,
RA   Manske M.K., Price-Troska T.L., Ziesmer S.C., Fonseca R., Witzig T.E.,
RA   Morice W.G. 2nd, Gertz M.A., Ansell S.M.;
RT   "Establishment and characterization of a novel Waldenstrom
RT   macroglobulinemia cell line, MWCL-1.";
RL   Blood 117:e190-e197(2011).
//
RX   PubMed=22950966; DOI=10.3109/10428194.2012.727418;
RA   Drexler H.G., Chen S., MacLeod R.A.F.;
RT   "Would the real Waldenstrom cell line please stand up?";
RL   Leuk. Lymphoma 54:224-226(2013).
//
RX   PubMed=23321251; DOI=10.1182/blood-2012-09-454355; PMCID=PMC3596964;
RA   Xu L., Hunter Z.R., Yang G., Zhou Y.-S., Cao Y., Liu X., Morra E.,
RA   Trojani A., Greco A., Arcaini L., Varettoni M., Brown J.R., Tai Y.-T.,
RA   Anderson K.C., Munshi N.C., Patterson C.J., Manning R.J.,
RA   Tripsas C.K., Lindeman N.I., Treon S.P.;
RT   "MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M
RT   monoclonal gammopathy, and other B-cell lymphoproliferative disorders
RT   using conventional and quantitative allele-specific polymerase chain
RT   reaction.";
RL   Blood 121:2051-2058(2013).
//
RX   PubMed=24189269; DOI=10.1038/labinvest.2013.129;
RA   Wada N., Zhan M.-S., Hori Y., Honma K., Ikeda J.-i., Morii E.;
RT   "Characterization of subpopulation lacking both B-cell and plasma cell
RT   markers in Waldenstrom macroglobulinemia cell line.";
RL   Lab. Invest. 94:79-88(2014).
//
RX   PubMed=25382610; DOI=10.1038/bcj.2014.74; PMCID=PMC5424099;
RA   Chitta K.S., Paulus A., Caulfield T.R., Akhtar S., Blake M.K.K.,
RA   Ailawadhi S., Knight J., Heckman M.G., Pinkerton A.B., Chanan-Khan A.A.;
RT   "Nimbolide targets BCL2 and induces apoptosis in preclinical models of
RT   Waldenstroms macroglobulinemia.";
RL   Blood Cancer J. 4:e260.1-e260.10(2014).
//
RX   PubMed=25853860; DOI=10.1371/journal.pone.0122338; PMCID=PMC4390194;
RA   Paulus A., Chitta K.S., Wallace P.K., Advani P.P., Akhtar S.,
RA   Blake M.K.K., Ailawadhi S., Chanan-Khan A.A.;
RT   "Immunophenotyping of Waldenstroms macroglobulinemia cell lines
RT   reveals distinct patterns of surface antigen expression: potential
RT   biological and therapeutic implications.";
RL   PLoS ONE 10:E0122338-E0122338(2015).
//